Back to top
more

Quest Diagnostics (DGX)

(Delayed Data from NYSE)

$153.56 USD

153.56
472,339

+0.72 (0.47%)

Updated Aug 23, 2024 04:00 PM ET

After-Market: $153.57 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 251)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Bruker (BRKR) Q2 Earnings Meet Mark, '24 Revenue Outlook Raised

Bruker (BRKR) delivers robust revenue growth in the second quarter despite soft general market conditions.

Stryker (SYK) Completes MOLLI's Acquisition to Boost Business

Stryker (SYK) completes of the acquisition of MOLLI, a privately held company, to strengthen its commitment to advancing surgical solutions in breast cancer care.

CooperCompanies (COO) Acquires obp Surgical to Boost Portfolio

CooperSurgical, a unit of CooperCompanies (COO), acquires obp Surgical for $100 million, adding innovative single-use surgical retractors and suction devices to its portfolio.

IDEXX (IDXX) Q2 Earnings Miss Estimates, 2024 View Down

IDEXX's (IDXX) Q2 earnings miss estimates but revenues meet the same.

Henry Schein (HSIC) Q2 Earnings Surpass, 2024 Guidance Slashed

Henry Schein's (HSIC) second-quarter results reflect an improvement in sales trends in distribution businesses.

Microbot Medical (MBOT) Inks Deal to Test Autonomous Robotics

Microbot Medical (MBOT) announces an agreement with Emory University to explore the potential of integrating robotics, procedure planning and navigation into a single autonomous system.

Inspire Medical (INSP) Gets FDA Nod for Inspire V System

Inspire Medical (INSP) secures FDA approval for its advanced Inspire V therapy system, featuring an innovative neurostimulator and Bluetooth technology for enhanced patient and physician control.

Tandem Diabetes (TNDM) Q2 Earnings Beat, '24 View Raised

Tandem Diabetes' (TNDM) top and bottom lines outpace estimates in the second quarter, backed by the demand for both t:slim X2 and the newly launched Tandem Mobi.

Quest Diagnostics Incorporated (DGX) Hit a 52 Week High, Can the Run Continue?

Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Ecolab (ECL) Sells Surgical Solutions Business to Medline

Ecolab's (ECL) deal to sell its global surgical solutions business to Medline enables it to focus on infection prevention and instrument reprocessing while enhancing shareholders' returns.

Bio-Rad (BIO) Q2 Earnings Surpass Estimates, Guidance Lowered

Bio-Rad (BIO) witnesses growth in the second quarter across the Clinical Diagnostics segment, primarily driven by an increased demand for quality control and blood typing products.

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Omnicell (OMCL) Q2 Earnings Top Estimates, Margins Down

Omnicell's (OMCL) Q2 results outpace expectations despite a challenging customer environment.

Teleflex (TFX) Tops Q2 Earnings Estimates, Raises 2024 Outlook

Teleflex's (TFX) diversified portfolio and global footprint have driven durable growth in the second quarter of 2024.

ResMed's (RMD) Q4 Earnings Surpass Estimates, Margins Expand

ResMed (RMD) delivers solid performance across all regions and business segments in the fourth quarter of fiscal 2024.

Mark Vickery headshot

Labcorp (LH) Q2 Earnings Surpass Estimates (revised)

Labcorp (LH) beats on earnings and revenues in the second quarter, entering the second half of 2024 with robust momentum.

BD (BDX) Q3 Earnings Surpass Estimates, Margins Expand

BD's (BDX) overall topline benefits from revenue growth in all segments in the fiscal third quarter.

Avanos (AVNS) Q2 Earnings Top Estimates, Gross Margin Contracts

Strength in Avanos' (AVNS) Digestive Health segment drives its second-quarter performance.

CONMED (CNMD) Q2 Earnings Beat, Sales Rise Y/Y, '24 View Cut

CONMED (CNMD) beats second-quarter earnings estimates on the back of higher revenues and lower costs and expenses. However, the result reflects the continued impact of supply chain issues.

Labcorp (LH) Q2 Earnings Surpass Estimates, Margins Increase

Labcorp (LH) beats on earnings and revenues in the second quarter, entering the second half of 2024 with robust momentum.

QIAGEN (QGEN) Q2 Earnings Surpass Estimates, Margins Crash

QIAGEN's (QGEN) earnings and revenues beat estimates in the second quarter. The company remains bullish on solid growth trends in the core business.

Zacks Industry Outlook Highlights Quest Diagnostics, DaVita, Encompass Health and Addus HomeCare

Quest Diagnostics, DaVita, Encompass Health and Addus HomeCare have been highlighted in this Industry Outlook article.

Stryker's (SYK) Q2 Earnings Beat Estimates, Guidance Raised

Stryker (SYK) beats second-quarter earnings estimates, driven by robust sales growth and innovative launches like the LIFEPAK 35 and Spine Guidance 5. The company raises 2024 guidance.

Debanjana Dey headshot

4 Stocks to Watch From a Challenging Outpatient Home Health Industry

Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DGX, DVA, EHC and ADUS are well-poised to gain.

Penumbra (PEN) Tops on Q2 Earnings, Lowers Sales View

Penumbra's (PEN) Thrombectomy product category shows encouraging growth trends, reflecting strong momentum in CAVT products.